van Erpecum Karel J, Portincasa Piero, van Berge Henegouwen Gerard P, Moschetta Antonio
Department of Gastroenterology and Hepatology University Medical Center, Utrecht, the Netherlands.
Division of Internal Medicine "A. Murri", Department of Precision and Regenerative and Ionian Area (DiMePre-J), University of Bari "Aldo Moro", Bari, Italy; Italian Educational Society for Precision Medicine (SIEMPRE), Rome, Italy.
Eur J Intern Med. 2025 Jul;137:4-10. doi: 10.1016/j.ejim.2025.04.009. Epub 2025 Apr 16.
Patients with low phospholipid-associated cholelithiasis may suffer from recurrent biliary symptoms and complications despite cholecystectomy and ursodeoxycholic acid therapy. Recently, beneficial clinical effects of treatment with the potent Farnesoid X receptor (i.e. bile salt receptor) agonist obeticholic acid in combination with ursodeoxycholic acid were reported in this patient group. In contrast, other studies reported more gallstone-related events and increased cholesterol saturation indices in gallbladder biles during obeticholic acid monotherapy. We here provide an in-depth review on solubilization and crystallization of cholesterol in bile, including all relevant physico-chemical aspects of cholesterol gallstone pathogenesis. We offer an explanation that reconciles seemingly contradictory data in previous publications. We propose that, due to the well-known inhibition of intra-hepatic bile salt synthesis from cholesterol by Farnesoid X receptor stimulation, biliary bile salt concentrations decrease during obeticholic acid therapy. As a result, biliary cholesterol solubilization shifts from mixed micelles into cholesterol-phospholipid vesicles, with inhibited cholesterol crystallization despite increased cholesterol saturation index (the latter takes only micellar cholesterol solubilization into account). We suggest that obeticholic acid has a lithoprotective effect, provided that increased bile salt hydrophobicity from obeticholic acid (a quite hydrophobic bile salt that is secreted into bile) is prevented by concomitant ursodeoxycholic acid therapy. We also suggest future directions for research into the role of obeticholic acid and other Farnesoid X receptor agonists to improve the prospects of low phospholipid-associated cholelithiasis patients and other gallstone patients with persisting biliary problems after cholecystectomy. In conclusion, obeticholic acid may enhance lithoprotective effects of ursodeoxycholic acid.
低磷脂相关胆石症患者即便接受了胆囊切除术和熊去氧胆酸治疗,仍可能反复出现胆系症状及并发症。最近,有报道称强效法尼酯X受体(即胆盐受体)激动剂奥贝胆酸联合熊去氧胆酸治疗该患者群体具有有益的临床效果。相比之下,其他研究报道奥贝胆酸单药治疗期间胆囊胆汁中更多与胆结石相关的事件以及胆固醇饱和指数升高。我们在此对胆汁中胆固醇的溶解和结晶进行深入综述,包括胆固醇胆结石发病机制的所有相关物理化学方面。我们给出一种解释,调和先前出版物中看似矛盾的数据。我们提出,由于法尼酯X受体刺激对胆固醇肝内胆盐合成的已知抑制作用,奥贝胆酸治疗期间胆汁胆盐浓度降低。结果,胆汁胆固醇溶解从混合微团转变为胆固醇 - 磷脂囊泡,尽管胆固醇饱和指数升高(后者仅考虑微团内胆固醇溶解),但胆固醇结晶受到抑制。我们认为,只要熊去氧胆酸治疗能防止奥贝胆酸(一种分泌到胆汁中的相当疏水的胆盐)导致的胆盐疏水性增加,奥贝胆酸就具有抗结石作用。我们还提出了未来研究方向,以探讨奥贝胆酸和其他法尼酯X受体激动剂在改善低磷脂相关胆石症患者及其他胆囊切除术后仍存在胆系问题的胆结石患者预后方面的作用。总之,奥贝胆酸可能增强熊去氧胆酸的抗结石作用。